An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine along with other Cancer Centers, suggests that an experimental therapy may have promising ...
May 26, 2023
0
4
Northwestern Medicine scientists have shed new light on how the deadliest form of thyroid cancer transforms from slow-growing to aggressive, according to research published in the Journal of Clinical Investigation.
May 22, 2023
0
24
University of Pittsburgh researchers have developed a universal receptor system that allows T cells to recognize any cell surface target, enabling highly customizable CAR T cell and other immunotherapies for treating cancer ...
May 9, 2023
0
69
Macrophages, a type of white blood cell, defend the body by engulfing and digesting foreign particles, such as bacteria, viruses, and dead cells. The immune cells also tend to accumulate in solid tumors, so tracking them ...
May 8, 2023
0
3
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can ...
Apr 25, 2023
0
11
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Apr 18, 2023
0
3
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair ...
Apr 18, 2023
0
9
Immunotherapy, particularly CAR T-Cell treatment for cancer, is extending the lives of many patients. But sometimes the therapy randomly migrates to places it shouldn't go, tucking into the lungs or other noncancerous tissue ...
Apr 17, 2023
0
33
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial ...
Apr 17, 2023
0
13
A new research paper titled "A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850" has been published in Oncotarget.
Apr 12, 2023
0
22
